Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Health & Healthcare

Illumina Partners With Centers Across France to Advance a Precision Medicine Approach for Patients With Late-Stage Cancer
Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests.

Health & Healthcare

Illuminating Rare Disease: Get to Know SLC6A1 Connect
Ahead of Rare Disease Day, Illumina is recognizing four rare disease patient organizations around the world. SLC6A1 Connect is the first in our series this month.

Health & Healthcare

Illumina Collaborates With National Cancer Center Japan to Address a Leading Cause of Death in Asia
Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical information of patients living with Nasopharyngeal Carcinoma.

Health & Healthcare

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Health & Healthcare

Illumina Partners With Agendia to Expand Genomic Testing in Breast Cancer Care
Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina's approach to IVD partnerships in oncology. Agendia joins Illumina's growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection and other applications.

Health & Healthcare

Illumina Collaborates With Nashville Biosciences to Accelerate Medicines Development
Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.

Innovation & Technology

Illumina Announces New Innovative Partnerships, Along With New Groundbreaking Technologies at 2022 J.P. Morgan Healthcare Conference
Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome.

Innovation & Technology

Illumina Enters Co-Development Partnership with SomaLogic to Help Researchers’ Understanding of Biology and Disease
Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms

Philanthropy & Cause Initiatives

Illumina Donates Over $14 Million to Local Communities and Volunteers More Than 6,000 Hours in 2021
As we wrap up 2021, we would like to thank our employees for giving back to our communities around the world.

Health & Healthcare

Illumina-Supported Startup Uses Tampons to Offer Critical Clues About Women's Reproductive Health
When entrepreneur Ridhi Tariyal walked out of Boston’s Brigham & Women’s Hospital in the fall of 2013, she left feeling frustrated.
Illumina logo

More from Illumina

  1. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  2. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...

  3. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  4. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  5. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  6. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...